Literature DB >> 6186684

Serum interferon in Navajo children with severe combined immunodeficiency disease inhibits lymphoblastogenesis.

J F Jones, L M Minnich, D O Lucas, V A Fulginiti, Z Ingham, M P Langford, G J Stanton.   

Abstract

Two Navajo Indian children with severe combined immunodeficiency disease (SCID) lost reconstituted immune function after virus infections. A serum factor which inhibited normal lymphocyte response to mitogens was found in one of them and led to the examination of sera from five other Navajos with SCID. Mean inhibition by six Navajo sera was 67%; no inhibitor was found in sera from normal adults and children. The inhibitor activity was nondialyzable and heat stable, yet partially sensitive to pH 2.0, suggesting that interferon(s) was present. Interferon (IFN) activity in patient sera ranged from 10 to 300 U/ml. Normal children had peak serum IFN levels of 100 and 30 U/ml in the acute and convalescent periods, respectively, of virus infections. IFN alpha, IFN beta, and IFN gamma were identified in SCID sera by specific antisera. Both inhibitor and IFN activities in three Navajo sera were 88-95 and 89-100%, respectively, removed with anti-IFN antisera. Similar patterns of inhibition of lymphoblastogenesis were seen with IFN standards. IFN levels in the SCID patients did not correlate with documented infections; elevated levels were present when no infections could be documented. The immunologic imbalances in some forms of SCID may be related to circulating inhibitors, possibly interferon.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6186684     DOI: 10.1007/bf00919134

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  23 in total

Review 1.  Host defenses against viral disease.

Authors:  T C Merigan
Journal:  N Engl J Med       Date:  1974-02-07       Impact factor: 91.245

Review 2.  Suppressor factors: potential for immunotherapy.

Authors:  R S Krakauer; J D Clough
Journal:  Immunopharmacology       Date:  1980-06

3.  Demonstration of an intrathymic defect in a case of severe combined immunodeficiency disease.

Authors:  K W Pyke; H Dosch; M M Ipp; E W Gelfand
Journal:  N Engl J Med       Date:  1975-08-28       Impact factor: 91.245

4.  Predominance of B-lymphocyte function after cultured thymus fragment therapy in severe combined immunodeficiency disease.

Authors:  J F Jones; O F Sieber; V A Fulginiti; H Ochs; H Schulte-Wisserman; R Hong
Journal:  Clin Immunol Immunopathol       Date:  1980-11

5.  Evaluation of T lymphocyte effector function in immunodeficiency diseases: abnormality in mitogen-stimulated interferon in patients with selective IgA deficiency.

Authors:  L B Epstein; A J Ammann
Journal:  J Immunol       Date:  1974-02       Impact factor: 5.422

6.  Biological effects of staphylococcal enterotoxin A on human peripheral lymphocytes.

Authors:  M P Langford; G J Stanton; H M Johnson
Journal:  Infect Immun       Date:  1978-10       Impact factor: 3.441

7.  Thymic dysplasia ("Swiss agammaglobulinemia"). II. Morphologic and functional observations.

Authors:  M E Miller; K Hummeler
Journal:  J Pediatr       Date:  1967-05       Impact factor: 4.406

8.  Immunoregulatory action of type I interferon in the mouse.

Authors:  E De Maeyer; J De Maeyer-Guignard
Journal:  Ann N Y Acad Sci       Date:  1980       Impact factor: 5.691

9.  Effect of an intramuscular injection of human leukocyte interferon on blood leukocyte counts and proportions of lymphocytes forming E, EA and EAC rosettes.

Authors:  S Einhorn; H Blomgren; H Strander
Journal:  Int Arch Allergy Appl Immunol       Date:  1980

10.  Effect of interferon therapy on circulating lymphocytes in humans.

Authors:  L Rasmussen; T C Merigan
Journal:  J Interferon Res       Date:  1980
View more
  2 in total

1.  Contradictory results in interferon research.

Authors:  G Sonnenfeld
Journal:  Surv Immunol Res       Date:  1984

2.  In vitro hyporeactivity to alpha-interferon in children with severe combined immunodeficiency disease.

Authors:  B R Williams; S E Read; E W Gelfand
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.